Gary A. Lyons, a director at Neurocrine Biosciences Inc. ($NBIX), sold shares on the open market once in the last year, totaling $2.29 million. His most recent sale occurred on December 3, 2025. These sales rank 3,226th among 11,678 individual insiders in our database, where the average sale amount is $8.59 million across about 6.4 transactions per insider. Lyons made no open market purchases during this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec. 3, 2025 | NEUROCRINE BIOSCIENCES INC | $NBIX | LYONS GARY A | Director | M | Common Stock | 15000 | $47.89 | 135,482.0000 | 102,500,000 | 12.45% | 0.01% |
| Dec. 3, 2025 | NEUROCRINE BIOSCIENCES INC | $NBIX | LYONS GARY A | Director | S | Common Stock | 15000 | $152.61 | 120,482.0000 | 102,500,000 | 11.07% | 0.01% |
| Dec. 3, 2025 | NEUROCRINE BIOSCIENCES INC | $NBIX | LYONS GARY A | Director | M | Non-Qualified Stock Option | 15000 | $0.00 | 0.0000 | 102,500,000 | 100.00% | 0.01% |
| May 22, 2025 | NEUROCRINE BIOSCIENCES INC | $NBIX | LYONS GARY A | Director | M | Common Stock | 1435 | $0.00 | 120,482.0000 | 103,700,000 | 1.21% | 0.00% |
| May 21, 2025 | NEUROCRINE BIOSCIENCES INC | $NBIX | LYONS GARY A | Director | A | Non-Qualified Stock Option | 3305 | $0.00 | 3,305.0000 | 103,700,000 | 9999.99% | 0.00% |
| May 22, 2025 | NEUROCRINE BIOSCIENCES INC | $NBIX | LYONS GARY A | Director | M | Restricted Stock Unit | 1435 | $0.00 | 0.0000 | 103,700,000 | 100.00% | 0.00% |
| May 21, 2025 | NEUROCRINE BIOSCIENCES INC | $NBIX | LYONS GARY A | Director | A | Restricted Stock Unit | 1659 | $0.00 | 1,659.0000 | 103,700,000 | 9999.99% | 0.00% |
| May 15, 2025 | Travere Therapeutics, Inc. | $TVTX | LYONS GARY A | Not found | A | Common Stock | 6500 | $0.00 | 57,500.0000 | 78,888,861 | 12.75% | 0.01% |
| May 15, 2025 | Travere Therapeutics, Inc. | $TVTX | LYONS GARY A | Not found | A | Stock option (right to buy) | 19500 | $0.00 | 19,500.0000 | 78,888,861 | 9999.99% | 0.02% |
| Oct. 4, 2024 | Travere Therapeutics, Inc. | $TVTX | LYONS GARY A | Not found | S | Common Stock | 18821 | $15.15 | 51,000.0000 | 77,779,379 | 26.96% | 0.02% |
| Oct. 4, 2024 | Travere Therapeutics, Inc. | $TVTX | LYONS GARY A | Not found | S | Common Stock | 21179 | $14.35 | 69,821.0000 | 77,779,379 | 23.27% | 0.03% |
| Oct. 4, 2024 | Travere Therapeutics, Inc. | $TVTX | LYONS GARY A | Not found | M | Common Stock | 40000 | $10.48 | 91,000.0000 | 77,779,379 | 78.43% | 0.05% |
| Oct. 4, 2024 | Travere Therapeutics, Inc. | $TVTX | LYONS GARY A | Not found | M | Stock option (right to buy) | 40000 | $0.00 | 0.0000 | 77,779,379 | 0.00% | 0.05% |
| Aug. 13, 2024 | NEUROCRINE BIOSCIENCES INC | $NBIX | LYONS GARY A | Director | S | Common Stock | 11570 | $150.43 | 119,047.0000 | 101,000,000 | 8.86% | 0.01% |
| Aug. 13, 2024 | NEUROCRINE BIOSCIENCES INC | $NBIX | LYONS GARY A | Director | M | Non-Qualified Stock Option | 11570 | $0.00 | 0.0000 | 101,000,000 | 100.00% | 0.01% |
| Aug. 13, 2024 | NEUROCRINE BIOSCIENCES INC | $NBIX | LYONS GARY A | Director | M | Common Stock | 11570 | $42.76 | 130,617.0000 | 101,000,000 | 9.72% | 0.01% |
| July 16, 2024 | NEUROCRINE BIOSCIENCES INC | $NBIX | LYONS GARY A | Director | S | Common Stock | 930 | $150.03 | 119,047.0000 | 101,000,000 | 0.78% | 0.00% |
| July 16, 2024 | NEUROCRINE BIOSCIENCES INC | $NBIX | LYONS GARY A | Director | M | Common Stock | 930 | $42.76 | 119,977.0000 | 101,000,000 | 0.78% | 0.00% |
| July 16, 2024 | NEUROCRINE BIOSCIENCES INC | $NBIX | LYONS GARY A | Director | M | Non-Qualified Stock Option | 930 | $0.00 | 11,570.0000 | 101,000,000 | 7.44% | 0.00% |
| May 22, 2024 | NEUROCRINE BIOSCIENCES INC | $NBIX | LYONS GARY A | Director | A | Non-Qualified Stock Option | 2982 | $0.00 | 2,982.0000 | 101,000,000 | 9999.99% | 0.00% |
| May 22, 2024 | NEUROCRINE BIOSCIENCES INC | $NBIX | LYONS GARY A | Director | A | Restricted Stock Unit | 1435 | $0.00 | 1,435.0000 | 101,000,000 | 9999.99% | 0.00% |
| May 17, 2024 | NEUROCRINE BIOSCIENCES INC | $NBIX | LYONS GARY A | Director | M | Restricted Stock Unit | 2100 | $0.00 | 0.0000 | 101,000,000 | 100.00% | 0.00% |
| May 17, 2024 | NEUROCRINE BIOSCIENCES INC | $NBIX | LYONS GARY A | Director | M | Common Stock | 2100 | $0.00 | 119,047.0000 | 101,000,000 | 1.80% | 0.00% |
| May 14, 2024 | NEUROCRINE BIOSCIENCES INC | $NBIX | LYONS GARY A | Director | M | Common Stock | 12500 | $42.76 | 129,447.0000 | 101,000,000 | 10.69% | 0.01% |
| May 14, 2024 | NEUROCRINE BIOSCIENCES INC | $NBIX | LYONS GARY A | Director | S | Common Stock | 12500 | $135.63 | 116,947.0000 | 101,000,000 | 9.66% | 0.01% |
| May 14, 2024 | NEUROCRINE BIOSCIENCES INC | $NBIX | LYONS GARY A | Director | M | Non-Qualified Stock Option | 12500 | $42.76 | 12,500.0000 | 101,000,000 | 50.00% | 0.01% |
| May 8, 2024 | Travere Therapeutics, Inc. | $TVTX | LYONS GARY A | Not found | A | Common Stock | 6500 | $0.00 | 51,000.0000 | 74,267,418 | 14.61% | 0.01% |
| May 8, 2024 | Travere Therapeutics, Inc. | $TVTX | LYONS GARY A | Not found | A | Stock option (right to buy) | 19500 | $0.00 | 19,500.0000 | 74,267,418 | 9999.99% | 0.03% |
| Dec. 22, 2023 | NEUROCRINE BIOSCIENCES INC | $NBIX | LYONS GARY A | Director | S | Common Stock | 10000 | $130.04 | 193,697.0000 | 98,900,000 | 4.91% | 0.01% |
| Dec. 1, 2023 | NEUROCRINE BIOSCIENCES INC | $NBIX | LYONS GARY A | Director | M | Common Stock | 5000 | $12.98 | 208,697.0000 | 98,900,000 | 2.45% | 0.01% |
| Dec. 1, 2023 | NEUROCRINE BIOSCIENCES INC | $NBIX | LYONS GARY A | Director | S | Common Stock | 5000 | $116.77 | 203,697.0000 | 98,900,000 | 2.40% | 0.01% |
| Dec. 1, 2023 | NEUROCRINE BIOSCIENCES INC | $NBIX | LYONS GARY A | Director | M | Non-Qualified Stock Option | 5000 | $12.98 | 0.0000 | 98,900,000 | 100.00% | 0.01% |
| Sept. 12, 2023 | NEUROCRINE BIOSCIENCES INC | $NBIX | LYONS GARY A | Director | M | Common Stock | 5000 | $12.98 | 208,697.0000 | 98,900,000 | 2.45% | 0.01% |
| Sept. 12, 2023 | NEUROCRINE BIOSCIENCES INC | $NBIX | LYONS GARY A | Director | S | Common Stock | 5000 | $115.02 | 203,697.0000 | 98,900,000 | 2.40% | 0.01% |
| Sept. 12, 2023 | NEUROCRINE BIOSCIENCES INC | $NBIX | LYONS GARY A | Director | M | Non-Qualified Stock Option | 5000 | $12.98 | 5,000.0000 | 98,900,000 | 50.00% | 0.01% |
| Sept. 1, 2023 | NEUROCRINE BIOSCIENCES INC | $NBIX | LYONS GARY A | Director | M | Common Stock | 5000 | $12.98 | 208,697.0000 | 98,900,000 | 2.45% | 0.01% |
| Sept. 1, 2023 | NEUROCRINE BIOSCIENCES INC | $NBIX | LYONS GARY A | Director | S | Common Stock | 5000 | $110.06 | 203,697.0000 | 98,900,000 | 2.40% | 0.01% |
| Sept. 1, 2023 | NEUROCRINE BIOSCIENCES INC | $NBIX | LYONS GARY A | Director | M | Non-Qualified Stock Option | 5000 | $12.98 | 10,000.0000 | 98,900,000 | 33.33% | 0.01% |
| May 26, 2023 | RIGEL PHARMACEUTICALS INC | $RIGL | LYONS GARY A | Not found | A | Stock Option (Right to Buy) | 30000 | $0.00 | 30,000.0000 | 173,568,000 | 9999.99% | 0.02% |
| May 26, 2023 | RIGEL PHARMACEUTICALS INC | $RIGL | LYONS GARY A | Not found | A | Common Stock | 25000 | $0.00 | 75,000.0000 | 173,568,000 | 50.00% | 0.01% |
| May 17, 2023 | NEUROCRINE BIOSCIENCES INC | $NBIX | LYONS GARY A | Director | A | Restricted Stock Unit | 2100 | $0.00 | 2,100.0000 | 98,900,000 | 9999.99% | 0.00% |
| May 17, 2023 | NEUROCRINE BIOSCIENCES INC | $NBIX | LYONS GARY A | Director | A | Non-Qualified Stock Option | 4290 | $0.00 | 4,290.0000 | 98,900,000 | 9999.99% | 0.00% |
| May 1, 2023 | Eledon Pharmaceuticals, Inc. | $ELDN | LYONS GARY A | Director | A | Common Stock | 150437 | $0.00 | 150,437.0000 | 0 | 9999.99% | 0.00% |
| Feb. 1, 2023 | Eledon Pharmaceuticals, Inc. | $ELDN | LYONS GARY A | Director | A | Stock Option (right to buy) | 20000 | $0.00 | 20,000.0000 | 0 | 9999.99% | 0.00% |